Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Ami Fadia

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Investors Business Daily

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia Pharmaceuticals led a biotech stock sell-off Wednesday after revenue from its Rett syndrome treatment missed expectations.

Investors Business Daily

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

Sage Therapeutics said Wednesday its Biogen-partnered treatment for essential tremor failed in a study, leading Sage stock to collapse.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Price

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.

Investors Business Daily

Mirati Rockets 33% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit

A treatment regimen from Mirati handily beat Merck's blockbuster Keytruda in some lung cancer patients, and MRTX stock rocketed Wednesday.

Investors Business Daily

'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover

Pfizer is in early talks to acquire cancer specialist Seagen, according to a report that sent SGEN stock flying on Monday.

Investors Business Daily

Why IBD 50 Stock Harmony Biosciences Surged Well Above A Buy Zone

Harmony crushed third-quarter forecasts and unveiled promising results for its narcolepsy drug — leading the biotech stock to surge Tuesday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga

Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat

Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged.

Investors Business Daily

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

Investors Business Daily

Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug

There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.